Bacchus Therapeutics

Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of cancer-causing gene MYC is virtually unmatched, making MYC one of the most frequently deregulated genes in human tumors, including, liver, kidney, brain, blood, breast, prostate, and lung tumors. Human studies and preclinical models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers. We developed innovative, proprietary small molecules that target fat metabolism. This causes regression of MYC cancers in preclinical mouse and human studies and prolongs survival. Moreover, our novel metabolomic platform allows us to screen which cancers will respond to our treatment. We are able to monitor therapeutic response within a few days of treatment by measuring the actual biomarkers of our cancer therapy. This allows us to tell patients and doctors if our drug is working much faster than for standard cancer treatments.